199 related articles for article (PubMed ID: 12775023)
1. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Usuki H; Ishimura K; Yachida S; Hagiike M; Okano K; Izuishi K; Karasawa Y; Goda F; Maeta H
Gastric Cancer; 2003; 6 Suppl 1():66-70. PubMed ID: 12775023
[TBL] [Abstract][Full Text] [Related]
2. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
[TBL] [Abstract][Full Text] [Related]
3. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
4. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Hoff PM
Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
[TBL] [Abstract][Full Text] [Related]
5. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.
Miyamoto S; Boku N; Ohtsu A; Yoshida S; Ochiai A; Okabe H; Fukushima M
Int J Oncol; 2000 Oct; 17(4):653-8. PubMed ID: 10995874
[TBL] [Abstract][Full Text] [Related]
7. Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
Shimizu T; Yamada Y; Yasui H; Shirao K; Fukuoka M
Anticancer Res; 2005; 25(4):2997-3001. PubMed ID: 16080558
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
9. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I nonsmall-cell lung cancer.
Nakagawa T; Tanaka F; Takata T; Matsuoka K; Miyahara R; Otake Y; Yanagihara K; Fukushimab M; Wada H
J Surg Oncol; 2002 Oct; 81(2):87-92. PubMed ID: 12355409
[TBL] [Abstract][Full Text] [Related]
11. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
Morimoto S; Shono Y; Tsuji T; Makihara K; Kawato N; Hachino Y; Mishima H; Tsujinaka T; Tabuse K
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2083-9. PubMed ID: 14712769
[TBL] [Abstract][Full Text] [Related]
12. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
Schmoll HJ
Anticancer Drugs; 2003 Oct; 14(9):695-702. PubMed ID: 14551502
[TBL] [Abstract][Full Text] [Related]
13. UFT and S-1 for treatment of primary lung cancer.
Tanaka F; Wada H; Fukushima M
Gen Thorac Cardiovasc Surg; 2010 Jan; 58(1):3-13. PubMed ID: 20058135
[TBL] [Abstract][Full Text] [Related]
14. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of dihydropyrimidine dehydrogenase inhibition.
Diasio RB
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):17-21. PubMed ID: 10442353
[TBL] [Abstract][Full Text] [Related]
16. Oral fluoropoyrimidines.
Hoff PM; Royce M; Medgyesy D; Brito R; Pazdur R
Semin Oncol; 1999 Dec; 26(6):640-6. PubMed ID: 10606257
[TBL] [Abstract][Full Text] [Related]
17. Dihydropyrimidine dehydrogenase-related enzymes predict efficacy and adverse reactions of UFT1+cisplatin neoadjuvant chemotherapy for gastric cancer.
Takiguchi N; Koda K; Ooshima H; Oda K; Suzuki H; Ishii R; Miyazaki M
Anticancer Drugs; 2002 Apr; 13(4):411-6. PubMed ID: 11984087
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer.
Baba H; Yamamoto M; Endo K; Ikeda Y; Toh Y; Kohnoe S; Okamura T
Gastric Cancer; 2003; 6 Suppl 1():45-9. PubMed ID: 12775020
[TBL] [Abstract][Full Text] [Related]
19. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
[TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.
Ichikawa W; Takahashi T; Suto K; Yamashita T; Nihei Z; Shirota Y; Shimizu M; Sasaki Y; Hirayama R
Br J Cancer; 2004 Oct; 91(7):1245-50. PubMed ID: 15354215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
